Dyne Therapeutics (DYN) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free DYN Stock Alerts $27.68 -1.07 (-3.72%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 8:00 AM | globenewswire.comDyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETMay 19 at 4:20 AM | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Down 3.2% After Insider SellingMay 19 at 2:20 AM | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Buy" from AnalystsMay 19 at 2:19 AM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to theMay 18 at 10:20 AM | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 2,588 SharesMay 18 at 4:40 AM | marketbeat.comRussell Investments Group Ltd. Reduces Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Russell Investments Group Ltd. reduced its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 100,496 shares of the company's stock after selling 46,650 shares durMay 17 at 10:35 PM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $73,162.76 in StockDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 2,588 shares of the firm's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $73,162.76. Following the completion of the transaction, the senior vice president now owns 116,695 shares in the company, valued at approximately $3,298,967.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.May 17 at 1:54 PM | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%May 16 at 3:39 PM | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38May 10, 2024 | americanbankingnews.comDyne Therapeutics, Inc. to Post FY2024 Earnings of ($2.87) Per Share, Chardan Capital Forecasts (NASDAQ:DYN)May 9, 2024 | marketbeat.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Chardan Capital issued their FY2024 earnings per share estimates for shares of Dyne Therapeutics in a research report issued on Monday, May 6th. Chardan Capital analyst K. Nakae expects that the company will earn ($2.87) per share fMay 9, 2024 | americanbankingnews.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:DYN)May 8, 2024 | marketbeat.comDyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report released on Monday, May 6th. Chardan Capital analyst K. Nakae forecasts that the company will post earningsMay 6, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)May 6, 2024 | marketbeat.comDyne Therapeutics' (DYN) Outperform Rating Reaffirmed at OppenheimerOppenheimer reissued an "outperform" rating and issued a $47.00 target price on shares of Dyne Therapeutics in a report on Monday.May 6, 2024 | markets.businessinsider.comRobust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne TherapeuticsMay 4, 2024 | finance.yahoo.comWe're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash WiselyMay 4, 2024 | finance.yahoo.comDyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst ProjectionsMay 3, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 3, 2024 | msn.comDYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 2, 2024 | globenewswire.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | msn.comMorgan Stanley Initiates Coverage of Dyne Therapeutics (DYN) with Overweight RecommendationApril 30, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46April 30, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Morgan StanleyMorgan Stanley started coverage on shares of Dyne Therapeutics in a report on Tuesday. They set an "overweight" rating and a $40.00 price objective on the stock.April 27, 2024 | marketbeat.comVivo Capital LLC Has $46.42 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Vivo Capital LLC lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 58.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,635,136 shares of the company's stock after purchasing an additional 600,000 sharesApril 26, 2024 | marketbeat.comFederated Hermes Inc. Invests $4.99 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)Federated Hermes Inc. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 375,000 shares of the company's stock, valued at approximately $4,988,0April 22, 2024 | finanznachrichten.deSynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTApril 14, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 18.5% in MarchDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 8,080,000 shares, a growth of 18.5% from the March 15th total of 6,820,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 16.2% of the shares of the company are sold short.April 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)April 4, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3%Dyne Therapeutics (NASDAQ:DYN) Trading Down 3%April 2, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 60.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,644 shares of the companMarch 27, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 9.9%Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 9.9%March 27, 2024 | globenewswire.comDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerMarch 27, 2024 | globenewswire.comDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumMarch 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)March 26, 2024 | marketbeat.comOppenheimer Reiterates "Outperform" Rating for Dyne Therapeutics (NASDAQ:DYN)Oppenheimer reaffirmed an "outperform" rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday.March 25, 2024 | bizjournals.comDyne announces CEO transition, former Biogen exec tapped for top spotMarch 25, 2024 | marketwatch.comDyne Therapeutics Shares Drop 14% on CEO Joshua Brumm DepartureMarch 25, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $28.24Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $28.24March 25, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO TransitionMarch 25, 2024 | markets.businessinsider.comDyne Therapeutics Appoints John Cox As CEO To Succeed Joshua BrummMarch 25, 2024 | marketwatch.comDyne Therapeutics CEO Joshua Brumm to Exit For Investing CareerMarch 25, 2024 | globenewswire.comDyne Therapeutics Announces CEO TransitionMarch 20, 2024 | fool.comDyne Therapeutics (NASDAQ: DYN)March 19, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest UpdateDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 29th, there was short interest totalling 6,610,000 shares, a decrease of 8.8% from the February 14th total of 7,250,000 shares. Based on an average daily volume of 1,980,000 shares, the short-interest ratio is currently 3.3 days. Approximately 16.6% of the company's shares are sold short.March 18, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.4%Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.4%March 18, 2024 | finance.yahoo.comDYN Apr 2024 30.000 putMarch 17, 2024 | marketbeat.comWalleye Capital LLC Takes $2.51 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Walleye Capital LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 280,276 shares of the company's stock, valued at approxiMarch 16, 2024 | finance.yahoo.comDYN Apr 2024 22.500 call Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. DYN Media Mentions By Week DYN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.140.42▲Average Medical News Sentiment DYN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼133▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PTC Therapeutics News Today Bausch Health Companies News Today MoonLake Immunotherapeutics News Today ACADIA Pharmaceuticals News Today Merus News Today Janux Therapeutics News Today Indivior News Today Rhythm Pharmaceuticals News Today TG Therapeutics News Today MorphoSys News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.